Company RXi Pharmaceuticals Corp OTC Bulletin Board
Equities
US74979C1053
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 14/09/17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 09/11/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Director/Board Member | 73 | 01/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 17/04/13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 06/06/17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 30/09/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 510,189 | 506,959 ( 99.37 %) | 0 | 99.37 % |
Company contact information
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.com![address RXi Pharmaceuticals Corp](https://cdn.zonebourse.com/static/address/10879186.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- PHIO Stock
- Stock
- Company RXi Pharmaceuticals Corp